Phase 4
Completed N=50
Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients
Source: ClinicalTrials.gov NCT03007225 ↗Enrolled (actual)
50
Serious AEs
12.0%
Results posted
Sep 2020
Primary outcomePrimary: Number of Participants With Complete Response — 23; 22 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study aimed to to compare the conventional transarterial chemoembolization (cTACE) with chemoembolization using doxorubicin drug eluting beads (DEB-TACE) for the treatment of hepatocellular carcinoma regarding short term efficacy and safety in first 3 months after embolization
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Complete Response |
23; 22 | — |
Eligibility Criteria
Inclusion Criteria
- Confirmed diagnosis of HCC according to the European association of study of liver diseases
- Early stage HCC (Stage A), using the Barcelona Clinic Liver Cancer (BCLC) staging system, (single or 3 nodules < 3cm PS 0) whenever curative measures were contraindicated and BCLC stage B (intermediate HCC).
- Patent portal vein and its main branches
- Informed consent from all participants before enrollment in the study.
Exclusion Criteria
- Patients with Child class C according to Child classification (BCLC D).
- Patients with diffuse HCC (non-measurable lesion).
- Patients with thrombosis of main portal vein or one of its main branches (BCLC C).
- Patients with extra hepatic invasion.
- patients refused to participate in the study
Data sourced from ClinicalTrials.gov (NCT03007225). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.